Literature DB >> 21255498

A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients.

Rachael L Parke1, Shay P McGuinness, Michelle L Eccleston.   

Abstract

OBJECTIVE: In a cardiothoracic and vascular intensive care unit, to compare nasal high-flow (NHF) oxygen therapy and standard high-flow face mask (HFFM) oxygen therapy in patients with mild to moderate hypoxemic respiratory failure.
METHODS: In a prospective randomized comparative study, 60 patients with mild to moderate hypoxemic respiratory failure were randomized to receive NHF or HFFM. We analyzed the success of allocated therapy, noninvasive ventilation rate, and oxygenation.
RESULTS: Significantly more NHF patients succeeded with their allocated therapy (P = .006). The rate of noninvasive ventilation in the NHF group was 3/29 (10%), compared with 8/27 (30%) in the HFFM group (P = .10). The NHF patients also had significantly fewer desaturations (P = .009).
CONCLUSIONS: NHF oxygen therapy may be more effective than HFFM in treating mild to moderate hypoxemic respiratory failure.

Entities:  

Mesh:

Year:  2011        PMID: 21255498     DOI: 10.4187/respcare.00801

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  49 in total

1.  High flow oxygen cannula: the other side of the moon.

Authors:  Alexandre Demoule; Jordi Rello
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

2.  Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.

Authors:  Byung Ju Kang; Younsuck Koh; Chae-Man Lim; Jin Won Huh; Seunghee Baek; Myongja Han; Hyun-Suk Seo; Hee Jung Suh; Ga Jin Seo; Eun Young Kim; Sang-Bum Hong
Journal:  Intensive Care Med       Date:  2015-02-18       Impact factor: 17.440

3.  High-flow nasal cannula is superior to noninvasive ventilation to prevent reintubation?

Authors:  Masaji Nishimura
Journal:  Ann Transl Med       Date:  2017-03

Review 4.  High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis.

Authors:  B Rochwerg; D Granton; D X Wang; Y Helviz; S Einav; J P Frat; A Mekontso-Dessap; A Schreiber; E Azoulay; A Mercat; A Demoule; V Lemiale; A Pesenti; E D Riviello; T Mauri; J Mancebo; L Brochard; K Burns
Journal:  Intensive Care Med       Date:  2019-03-19       Impact factor: 17.440

5.  High-efficiency generation and delivery of aerosols through nasal cannula during noninvasive ventilation.

Authors:  P Worth Longest; Ross L Walenga; Yoen-Ju Son; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-12-28       Impact factor: 2.849

6.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

7.  Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.

Authors:  P Worth Longest; Laleh Golshahi; Srinivas R B Behara; Geng Tian; Dale R Farkas; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-05       Impact factor: 2.849

8.  Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI ≥30: a randomised controlled trial.

Authors:  Amanda Corley; Taressa Bull; Amy J Spooner; Adrian G Barnett; John F Fraser
Journal:  Intensive Care Med       Date:  2015-04-08       Impact factor: 17.440

9.  High flow nasal oxygen therapy utilization: 7-year experience at a community teaching hospital.

Authors:  Mihaela S Stefan; Patrick Eckert; Bogdan Tiru; Jennifer Friderici; Peter K Lindenauer; Jay S Steingrub
Journal:  Hosp Pract (1995)       Date:  2018-02-15

10.  Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components.

Authors:  P Worth Longest; Laleh Golshahi; Michael Hindle
Journal:  Ann Biomed Eng       Date:  2013-02-20       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.